PEBP1 and STK11 transcript levels were associated with immunosuppressive properties and responses to immune checkpoint blockade (ICB) therapies, such as anti-PD1 and anti-CTLA4, particularly in melanoma, kidney, and lung cancers. Here, STK11 is linked to lung carcinoma.